WO2016050734A1 - Combinaisons d'inhibiteurs de la recapture de la norépinéphrine et de la sérotonine et sources de folate - Google Patents

Combinaisons d'inhibiteurs de la recapture de la norépinéphrine et de la sérotonine et sources de folate Download PDF

Info

Publication number
WO2016050734A1
WO2016050734A1 PCT/EP2015/072362 EP2015072362W WO2016050734A1 WO 2016050734 A1 WO2016050734 A1 WO 2016050734A1 EP 2015072362 W EP2015072362 W EP 2015072362W WO 2016050734 A1 WO2016050734 A1 WO 2016050734A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical combination
folate
combination according
methylfolate
weight
Prior art date
Application number
PCT/EP2015/072362
Other languages
English (en)
Inventor
Ali TÜRKYILMAZ
Nur PEHLIVAN AKALIN
Merve AYHAN
Sibel ZENGINER
Hilal ÖZGÖRÜR
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret A.S. filed Critical Sanovel Ilac Sanayi Ve Ticaret A.S.
Publication of WO2016050734A1 publication Critical patent/WO2016050734A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Definitions

  • the present invention relates to a pharmaceutical combination comprising a serotonin norepinephrine reuptake inhibitor and a folate source. More specifically, this invention relates to a pharmaceutical combination comprising duloxetine or a pharmaceutically acceptable salt thereof in combination with a folate source.
  • Antidepressants work by increasing the amount of neurotransmitters active in the synapse, thereby enhancing neuronal activity and increasing the responsiveness of mood. Modern antidepressants usually achieve this effect by blocking the transporter proteins that reabsorb certain neurotranmitters, hence the name “reuptake inhibitors”.
  • the serotonin norepinephrine reuptake inhibitors are a group of compounds typically used as antidepressants in the treatment of major depressive disorder (depression), anxiety disorders, obsessive-compulsive disorder (OCD), attention deficit hyperactivity disorder (ADHD), chronic neuropathic pain, fibromyalgia syndrome (FMS) for the relief of menopausal symptoms and some personality disorders.
  • Serotonin and norepinephrine are neurotransmitters which carry massages to the brain. Serotonin can elevate mood and cause a calming effect. Norepinephrine can increase alertness, concentration and motivation. After carrying messages, serotonin and norepinephrine are usually reuptake by the nerve cells. Serotonin-norepinephrine reuptake inhibitors (SNRIs) block or delay the reuptake of these neurotransmitters. This increases the levels of these two neurotransmitters in the synapse and tends to relieve depression and other mood disorders.
  • SNRIs Serotonin-norepinephrine reuptake inhibitors
  • Serotonin-norepinephrine reuptake inhibitors include desvenlafaxine (Pristiq), venlafaxine (Effexor), milnacipran (Dalcipran), levomilnacipran (Fetzima), sibutramine (Meridia) and duloxetine (Cymbalta) and they are all authorized for the depression treatment.
  • Duloxetine inhibits serotonin and norepinephrine reuptake at all doses. It is extensively metabolized in the liver to numerous metabolites. The half-life is approximately 12 hours.
  • Folic acid also called folate or folacin
  • folate is necessary for the proper biosynthesis of the monoamine neurotransmitters serotonin, norepinephrine, epinephrine, and dopamine.Researches show that people with depression and low folate levels are less likely to respond to treatments such as antidepressants and less likely to achieve remission. While SNRIs block the reuptake of neuratransmitters, folate helps to further increase these neurotransmitters. For these reasons, during the treatment of depression, folate sources are recommended as an additional supplement to improve the efficacy of treatment on patients.
  • L-methylfolate (Deplin)
  • MTHF Methyl folate, Methyltetrahydrofolate, methyltetrahydrofolic acid
  • SAMe S-adenosylmethionine
  • L-methylfolate medical source of folate that can cross the blood brain barrier and help with the synthesis of the neurotransmitters associated with mood and, consequently, mood disorders such as depression.
  • a pharmaceutical combination comprising duloxetine or a pharmaceutically acceptable salt thereof in combination with a folate source has been developed to achieve a stable pharmaceutical combination with a safe and effective release.
  • the main embodiment of this present invention is to provide a pharmaceutical combination comprising duloxetine or a pharmaceutically acceptable salt thereof in combination with a folate source.
  • One embodiment of this present invention is to provide a pharmaceutical combination comprising duloxetine or a pharmaceutically acceptable salt thereof in combination with a folate source has been developed to achieve a stable pharmaceutical combination with a safe and effective dissolution profile.
  • folate source used in the pharmaceutical combination of this present invention is selected from the group comprising L-methylfolate, L-methylfolate calcium, folic acid (pteroylglutamic acid), vitamin B or other pharmaceutically acceptable folate source, preferably L-methyl folate.
  • duloxetine or a pharmaceutically acceptable salt thereof is present in an amount of between 5 - 90%, preferably 15 - 50% and more preferably 10 - 20% by weight of total formulation.
  • L-methylfolate is present in an amount of between 1 - 30%, preferably 2 - 20%, more preferably 2 - 10% by weight of total formulation.
  • the ratio of duloxetine to L-methylfolate is in the range of 1 to 20 (w/w), preferably 1 to 10 (w/w), more preferably 1 to 5 (w/w).
  • the pharmaceutical combination is in the form of a capsule, gelatin capsule, tablet, bilayer tablet, multilayer tablet, mini tablet, oral granule, powder or sachet.
  • Duloxetine is water soluble, while L-methyl folate is water non-soluble. Due to solubility difference of two active agents, they pressed into different forms with different excipients. Moreover, with these two forms in one capsule, while stability is achieved, safe and efficient dissolution profile of both active agent is also achieved.
  • the pharmaceutical combination is in the form of a capsule comprising pellets and mini tablets.
  • Pellets comprise duloxetine and mini tablets comprise L-methyl folate.
  • duloxetin or a pharmaceutically acceptable salt thereof is present in an amount of between 14 - 25% by weight of pellet.
  • L-methylfolate is present in an amount of between 40 - 50% by weight of mini tablet.
  • the SNRI used in the formulation may also be desvenlafaxine (Pristiq), venlafaxine (Effexor), milnacipran (Dalcipran), levomilnacipran (Fetzima) and sibutramine (Meridia).
  • pharmaceutical combination of this present invention comprise at least one pharmaceutical excipient selected from the group comprising disintegrants, binders, diluents, glidants, lubricants or mixtures thereof.
  • Suitable disintegrants are selected from the group comprising sodium starch glycolate, HPMC (hydroxylpropyl methyl cellulose), cross-linked polyvinylpyrrolidone (crospovidon or copovidon), croscarmellose sodium, low-substitue HPC (hydroxylpropyl cellulose), microcristalline cellulose, starch, alginic acid and alginates, ion-exchange resins, magnesium aluminum silica, sodium dodecyl sulphate, sodium carboxy methyl cellulose, carboxy methyl cellulose calcium, docusate sodium, guar gam, polyacrylin potasium, poloxomer, sodium alginate, sodium glysin carbonate, sodium lauryl sulphate or mixtures thereof.
  • Suitable binders are selected from the group comprising starch, cellulose, polyvinylpyrrolidone (povidone), polymethacrylate, poloxamer, glyceryl behenate, hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), carboxymethyl cellulose (CMC), methyl cellulose (MC), hydroxyethyl cellulose, sodium carboxymethyl cellulose (Na CMC), carboxymethyl cellulose calcium, ethyl cellulose and other cellulose derivatives, polymetacrylates, polyethylene oxide, polyvinyl alcohol, polyvinyl acetate and their copolymers, gelatin, xanthan gum, guar gum, alginate, pullulan, carrageen, kollagen, agar, pectin, hyaluronic acid, carbomer, cellulose acetate phthalate, hydroxypropyl starch, hydroxyethyl methyl cellulose, polyethylene glycol (PEG), sugars,
  • Suitable diluents are selected from the group comprising mannitol, sucrose, lactose anhydrate, microcrystalline cellulose, sorbitol, trehalose, isomalt, starch, calcium phosphate anhydrate, calcium phosphate dihydrate, calcium phosphate trihydrate, dibasic calcium phosphate, tribasic calcium phosphate, calcium carbonate, calcium sulfate, carboxymethyl cellulose calcium, powdered cellulose, cellulose acetate, pregelatinized starch, lactose monohydrate, sodium carbonate, sodium bicarbonate, maltodextrine, dextrose, izomalt, calcium carbonate, xylitol, corn starch or mixtures thereof.
  • Suitable glidants are selected from the group comprising colloidal silicon dioxide (aerosil), talk, aluminum silicate, powdered cellulose, calcium phosphate tribasic, hydrophobic colloidal silica, magnesium oxide, magnesium trisilicate, magnesium silicate or mixtures thereof.
  • Suitable lubricants are selected from the group comprising poloxamer, sodium lauryl sulphate, magnesium stearate, calcium stearate, mineral oil, sodium stearyl fumarate, talk, polyethylene glycol, glyceryl monostearate, glyceryl palmitostearate, magnesium lauryl sulphate, fumaric acid, zinc stearate, stearic acid, hydrogenated natural oils, silica, paraffin or mixtures thereof. Coating may also preferably be used for the combination.
  • It can be selected from the group comprising poly(methacrylic acid - ethyl acrylate) (1 :1 ), talc, polyvinyl alcohol- polyethylene glycol copolymers (Kollicoat IR), polyvinyl alcohol or copolymers or mixtures thereof (Opadry AMB), Ethylcellulose Dispersions (Surelease), Kerry-HPC, polyethylene glycol, polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer(PVP-VA) and all kinds of OpadryTM, as well as pigments, dyes, titanium dioxide, iron oxide and polymethylmetacrylate copolymers (Eudragit).
  • Plasticizers may include, but not limited to tributyl citrate, triethyl citrate (TEC) ,diethyl phthalate (DEP), dibutyl sebacate (DBS), acetylated monoglycerides, triacetin or acetyltriethyl citrate.
  • TEC triethyl citrate
  • DEP diethyl phthalate
  • DBS dibutyl sebacate
  • acetylated monoglycerides triacetin or acetyltriethyl citrate.
  • duloxetine and folate source combinations comprising of the following: Pellets;
  • duloxetin or pharmaceutically acceptable salt thereof
  • Mini tablets
  • magnesium stearate - 0.01 - 5.0 % by weight of magnesium stearate
  • Pellet preparation duloxetine, mannitol, starch and talk are mixed. A solution is prepared with ethyl alcohol, povidone, poloxamer, purified water and sucrose. Mixture containing duloxetin is applicated on cellulose pellets by this syrup. Observed wet pellets are dried. Subcoating of pellets is done by HPMC (E5), Tributhyl citrate, ethyl alcohol and talk. Then, enteric coating is done by poly(methacrylic acid - ethyl acrylate) 1 : 1 mixture, Tributhyl citrate and water. Enteric coated pellets are sieved and dried.
  • HPMC E5
  • Tributhyl citrate Tributhyl citrate
  • enteric coated pellets are sieved and dried.
  • Mini tablet preparation L-methyl folate, lactose anhydrate and sodium starch glycolate are mixed. Aerosil and magnesium sterate are added to mixture and mixed again. Total homogenous mixture compressed into mini tablets.
  • pellets comprising duloxetine and mini tablets comprising L-methylfolate are filled into capsules.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une combinaison pharmaceutique comprenant un inhibiteur du recaptage de la sérotonine-norépinéphrine et un folate source.
PCT/EP2015/072362 2014-09-30 2015-09-29 Combinaisons d'inhibiteurs de la recapture de la norépinéphrine et de la sérotonine et sources de folate WO2016050734A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2014/11491 2014-09-30
TR201411491 2014-09-30

Publications (1)

Publication Number Publication Date
WO2016050734A1 true WO2016050734A1 (fr) 2016-04-07

Family

ID=54324941

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/072362 WO2016050734A1 (fr) 2014-09-30 2015-09-29 Combinaisons d'inhibiteurs de la recapture de la norépinéphrine et de la sérotonine et sources de folate

Country Status (1)

Country Link
WO (1) WO2016050734A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011642A1 (fr) * 2003-08-05 2005-02-10 Galephar M/F Composition pharmaceutique a unite simple comprenant un melange de fibranne et un agent reducteur d'homocysteine
WO2008129501A2 (fr) * 2007-04-20 2008-10-30 Wockhardt Research Centre Compositions pharmaceutiques de duloxetine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011642A1 (fr) * 2003-08-05 2005-02-10 Galephar M/F Composition pharmaceutique a unite simple comprenant un melange de fibranne et un agent reducteur d'homocysteine
WO2008129501A2 (fr) * 2007-04-20 2008-10-30 Wockhardt Research Centre Compositions pharmaceutiques de duloxetine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SIRISHA K V R ET AL: "A review of pellets and pelletization process - a multiparticulate drug delivery system", INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH 2013 SOCIETY OF PHARMACEUTICAL SCIENCES AND RESEARCH IND, vol. 4, no. 6, 2013, pages 2145 - 2158, XP002752069, ISSN: 2320-5148 *
WADE ROLIN L ET AL: "Comparative assessment of adherence measures and resource use in SSRI/SNRI-treated patients with depression using second-generation antipsychotics or L-methylfolate as adjunctive therapy.", JOURNAL OF MANAGED CARE PHARMACY : JMCP JAN 2014, vol. 20, no. 1, January 2014 (2014-01-01), pages 76 - 85, XP009187654, ISSN: 1944-706X *

Similar Documents

Publication Publication Date Title
US20210085635A1 (en) Use of levodopa, carbidopa and entacapone for treating parkinson's disease
ES2619329T3 (es) Composiciones de tapentadol
US9937132B2 (en) Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
JP2022033758A (ja) 生理活性の強い、ｕｒａｔ１のインヒビターを含む医薬組成物
JP2008280351A (ja) テルビナフィンを含有する医薬組成物およびその使用
US20230078925A1 (en) Pulsatile drug delivery system for treating morning akinesia
US20070184110A1 (en) Dipyridamole extended-release formulations and process for preparing same
EP3518910A1 (fr) Compositions de midodrine et leurs procédés d'utilisation
KR20180133503A (ko) 메살라진의 경구용 약제학적 조성물
WO2018122384A1 (fr) Compositions pharmaceutiques orales comprenant du tadalafil et de la dapoxétine
JP2022529189A (ja) 持続放出製剤
US20180015080A1 (en) Compositions and methods for treatment in parkinson's disease patients
EP2848242A1 (fr) Formulations orodispersibles de Linagliptin
JP2023181218A (ja) 持続放出ミドドリン塩酸塩組成物及び使用方法
ES2668379T3 (es) Método para el tratamiento de trastornos del movimiento con befiradol
KR101497354B1 (ko) 활성 성분으로 에페리손을 함유하는 서방성 제제 조성물
WO2020009675A2 (fr) Compositoins pharmaceutiques solides d'administration par voie orale comprenant de la linagliptine
US20160235776A1 (en) Sustained-release compositions comprising topiramate and an alkalizer
EP3366291A1 (fr) Compositions pharmaceutiques orales solides comprenant de l'acide lipoïque alpha et des vitamines solubles dans l'eau
WO2016050734A1 (fr) Combinaisons d'inhibiteurs de la recapture de la norépinéphrine et de la sérotonine et sources de folate
EP3338767A1 (fr) Compositions de capsule comprenant du donépézil et de la mémantine
EP3238714A1 (fr) Formulations à libération prolongée de flurbiprofène et de tramadol
EP2959901A1 (fr) Combinaisons pharmaceutiques de sofosbuvir et ribavirine
EP3366290A1 (fr) Compositions pharmaceutiques orales comprenant de l'acide lipoïque alpha et vitamines solubles dans l'eau
TWI654977B (zh) 用於控管噁心及嘔吐之組合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15780788

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15780788

Country of ref document: EP

Kind code of ref document: A1